<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01269996</url>
  </required_header>
  <id_info>
    <org_study_id>CRE-2010.523</org_study_id>
    <nct_id>NCT01269996</nct_id>
  </id_info>
  <brief_title>JanUmet Before Insulin Lantus In Eastern Population Evaluation Program (JUBILEE) In Type 2 Diabetic Patients</brief_title>
  <acronym>JUBILEE</acronym>
  <official_title>JanUmet Before Insulin Lantus In Eastern Population Evaluation Program (JUBILEE) In Type 2 Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of a new treatment regimen of metformin plus sitagliptin
      (Janumet) followed by a long-acting basal insulin (Lantus) treatment compared to the usual
      treatment regimen of metformin followed by sulfonylurea and intermediate-acting basal insulin
      in Type 2 Diabetes Mellitus patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type 2 diabetes mellitus (T2DM) accounts for more than 90% of all diabetes. The worldwide
      prevalence of T2DM is increasing.

      Microvascular and macrovascular complications are well known to cause significant morbidities
      and shorten life expectancy in diabetic patients. T2DM is the leading cause of adult-onset
      blindness, renal failure, limbs amputation, ischaemic heart disease and stroke in the
      industrialized world. Progressive pancreatic beta-cell failure together with insulin
      resistance underlie the pathogenesis of T2DM.

      Glycaemic control is essential and fundamental to the management of diabetes. Randomized
      control trials have confirmed the long term benefits of achieving glycaemic control early in
      the course of disease on future clinical outcomes. Long term follow up of The Diabetes
      Control and Complications Trial Research Group (DCCT) and U.K. Prospective Diabetes Study
      (UKPDS) cohorts showed that improving glycaemic control reduces the incidences of both
      microvascular and macrovascular complications.

      It is generally agreed that HbA1c &lt;7% is a reasonable goal in adults to reduce risk of
      diabetes complications. Subgroup analyses of DCCT and UKPDS and results of Action in Diabetes
      and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE)
      trial suggest a small but incremental benefit in microvascular outcomes with HbA1c values
      closer to normal. In the subgroup analysis of the ACCORD study, subjects without history of
      cardiovascular disease and attained HbA1c goal of 6.5% had lower risk of cardiovascular
      endpoints than those with HbA1c goal of 7%. Therefore, selected individual patients including
      those with short duration of diabetes, long life expectancy and no significant cardiovascular
      disease, may benefit from a more stringent HbA1c goal of &lt;6.5%, a value close to normal
      individual.

      According to the American Diabetes Association (ADA) and the European Association for the
      Study of Diabetes, lifestyle modification plus Metformin is a well-validated step 1 therapy
      for patients with T2DM. Sulfonylurea or insulin treatment formed the step 2 therapy in those
      who fail to achieve optimal glycaemic control after step 1 treatment. Sulfonylurea is an
      insulin secretagogue. It acts in a glucose-independent fashion by increasing the insulin
      concentration irrespective of the ambient glucose concentration. Despite its efficacy, it is
      associated with increased risk of hypoglycaemia and weight gain.

      Incretins are gut-derived hormones that include Glucagon-like peptide-1 (GLP-1) and
      Glucose-dependent insulinotropic peptide (GIP). Incretins are released into the circulation
      after a meal. Both GLP-1 and GIP stimulate endogenous insulin secretion in a
      glucose-dependent fashion. They also inhibit glucagon secretion, delay gastric emptying and
      induce satiety. The combined effect of incretins in augmenting insulin secretion and
      suppressing glucagon reduces post-prandial glucose excursion. In animal models, GLP-1 has
      also been shown to preserve pancreatic beta-cell mass by increased proliferation and
      decreased apoptosis. In T2DM patients, the attenuated post-prandial GLP-1 secretion may
      partially explain the increased post-prandial rise in glucose concentration.

      However, incretins have very short half-lives of a few minutes. They are rapidly inactivated
      by the enzyme dipeptidyl peptidase IV (DPP-4) in the circulation. Inhibitors of the enzyme
      DPP-4 can augment active incretin levels by delaying the clearance of the active incretins,
      hence augmenting the incretin action with resultant improvement in glycaemic control in T2DM
      patients.

      In later stage of T2DM, progressive pancreatic beta-cell failure frequently results in
      deterioration in glycaemic control despite oral drug treatment, necessitating supplementary
      insulin therapy. New generations of once-daily, long-acting basal insulin may have better
      safety profile in terms of less hypoglycaemic events compared with traditional
      intermediate-acting basal insulin. Supplementary basal insulin, when titrated appropriately,
      will almost always improve fasting blood glucose levels and HbA1c control.

      Sitagliptin is an orally active, potent and highly selective DPP-4 inhibitor which was
      approved by the U.S. Food and Drug Administration (FDA) in October 2006 as a new class of
      oral drug treatment for T2DM. Sitagliptin is marketed as Januvia by Merck &amp; Co. In April
      2007, the FDA approved an oral combination of sitagliptin and metformin marketed as Janumet
      with preparations of 50/500mg and 50/1000mg dosage per tablet. Sitagliptin has been proved to
      be effective in treating T2DM with minimal risk of hypoglycaemia together with additional
      benefits on reducing glucagon, slowing gastric emptying and inducing satiety.

      Insulin glargine, marketed by Sanofi Aventis under the name Lantus, is a long-acting basal
      insulin analogue. It has the advantage of a long action duration of 18 to 26 hours and a
      peakless profile, which resembles basal insulin secretion of non-diabetic pancreatic
      beta-cells.

      In T2DM patients, we proposed that a new treatment regimen consists of a combination of
      DPP-IV inhibitor plus metformin followed by long-acting basal insulin may be more effective
      in achieving good and sustained glycaemic control with less hypoglycaemic drawbacks compared
      with the traditional regimen of metformin followed by sulfonylurea and finally
      intermediate-acting insulin. This proposed new treatment regimen forms the basis of this
      study.

      The objective of this multicentre, randomized, open-label prospective study is to evaluate
      the efficacy and safety of a new treatment regimen of metformin plus sitagliptin (Janumet)
      followed by a long-acting basal insulin (Lantus) treatment compared to the usual treatment
      regimen of metformin follow by sulfonylurea and intermediate-acting basal insulin in T2DM
      patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the treatment efficacy</measure>
    <time_frame>one year</time_frame>
    <description>The change in HbA1c in 1 year compare to baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>proportion of patients with HbA1c &lt;6.5% in 1 year</measure>
    <time_frame>one year</time_frame>
    <description>Secondary Outcome Measure: The proportion of patients with HbA1c &lt;6.5% in 1 year.
Other outcome measures: a)The change in body weight compare to baseline. b)Frequency of hypoglycaemia . Hypoglycemia is defined according to the ADA definitions and classifications of hypoglycaemia.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Metformin followed by gliclazide and protaphane</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Janumet followed by Lantus insulin injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Janumet, Lantus</intervention_name>
    <description>In this multicentre, randomized, open-label prospective study. Recruited patients will be randomized to one of the two treatment groups. Treatment efficacy and safety in terms of HbA1c control and hypoglycemic events will be evaluated.
Treatment groups:
Group 1 - Metformin followed by Sulfonylurea (Gliclazide) and supplementary intermediate-acting insulin (Protaphane) injection.
Group 2 - Janumet followed by Lantus insulin injection.</description>
    <arm_group_label>Metformin followed by gliclazide and protaphane</arm_group_label>
    <arm_group_label>Janumet followed by Lantus insulin injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin, gliclazide, protaphane</intervention_name>
    <description>In this multicentre, randomized, open-label prospective study. Recruited patients will be randomized to one of the two treatment groups. Treatment efficacy and safety in terms of HbA1c control and hypoglycemic events will be evaluated.
Treatment groups:
Group 1 - Metformin followed by Sulfonylurea (Gliclazide) and supplementary intermediate-acting insulin (Protaphane) injection.
Group 2 - Janumet followed by Lantus insulin injection.</description>
    <arm_group_label>Metformin followed by gliclazide and protaphane</arm_group_label>
    <arm_group_label>Janumet followed by Lantus insulin injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult patients aged 18 to 80 years old at Visit 1.

          2. Male or female of Chinese ethnicity.

          3. Type 2 diabetic patients who are drug na√Øve with HbA1c ranged between 7.0% to 11.0%.

          4. Type 2 diabetic patients who are on single oral hypoglycaemic drug treatment or
             insulin treatment of duration less than 6 months are eligible after at least 3 months
             of washout period with diet control only prior to Visit 1 and satisfy the inclusion
             criteria of HbA1c ranged between 7.0% to 11.0%.

          5. Patient understands the study procedures, alternative treatments available, and the
             risks involved with the study, and voluntarily agrees to participate by providing
             written informed consent.

          6. Patient agrees to provide permission to obtain all medical records necessary for
             complete data ascertainment during study and follow-up period.

        Exclusion Criteria:

          1. Patient has a history of type 1 diabetes mellitus or a history of ketoacidosis.

          2. Patients with HbA1c 9% to 11% who have severe symptoms and showing signs of
             decompensation (e.g. rapid weight loss and ketonuria) due to hyperglycaemia.

          3. On anti-obesity drugs 12 weeks prior to informed consent, patient in a weight loss
             program or intends to be involved in weight loss intervention outside that prescribed
             by the study.

          4. Patient has renal impairment defined as serum creatinine equal to/more than 123 umol/l
             (1.4mg/dL) in female and serum creatinine equal to/more than 132 umol/l (1.5mg/dL) in
             male.

          5. Significant liver impairment (ALT equal to /more than 2 times upper limit of normal
             range) or a medical history of active liver disease (other than non-alcoholic hepatic
             steatosis), including chronic active hepatitis B or C, primary biliary cirrhosis,
             liver cirrhosis or symptomatic gallbladder disease.

          6. Any history of cardiovascular disease, stroke or peripheral vascular disease.

          7. Any symptoms of ischaemic heart disease like angina.

          8. Renal transplant patients.

          9. Active malignant disease. Patients with malignant disease who have been successfully
             treated and disease-free for at least 5 years are eligible. However, patients with a
             history of leukaemia, lymphoma, aplastic anaemia, myeloproliferative or
             myelodysplastic disease, thrombocytopenia, malignant melanoma, or renal cell carcinoma
             are ineligible for the study regardless of the time since treatment.

         10. Patient has medical history that indicates a life expectancy of less than 5 years or
             might limit the individual's ability to take trial treatments for the duration of the
             study.

         11. Patient has a history or current evidence of any condition, therapy, laboratory
             abnormality, or other circumstance which, in the opinion of the investigator or
             coordinator, might pose a risk to the patient, make participation not in the patient's
             best interest, confound the results of the study (e.g. if patient cannot comply with
             requirements of the study), or interfere with the patient's participation for the full
             duration of the study.

         12. Patient has a known history of hypersensitivity, intolerance or any contraindication
             to either metformin, sulfonylurea, DPP-IV inhibitor or insulin.

         13. Active and uncontrolled thyroid diseases or active endocrine diseases like Cushing's
             syndrome or acromegaly.

         14. Pre-menopausal women (last menstruation 1 year prior to signing informed consent) who:
             are nursing or pregnant, or are of child-bearing potential and are not practicing an
             acceptable and reliable contraceptive methods, or do not plan to continue using this
             method throughout the study and do not agree to submit to periodic pregnancy testing
             during participation in the trial. Acceptable methods of birth control include
             transdermal patch, intra-uterine devices/systems (IUDs/IUSs), oral, implantable or
             injectable contraceptives, sexual abstinence and vasectomised partner. No exception
             will be made.

         15. Any medical illness or condition as judged by the investigators as ineligible to
             participate the study.

         16. Special population, e.g. prisoner, mentally disabled, persons with psychiatric
             disorders and investigators' student or employees.

         17. Patient is currently participating in or has participated in another study with an
             investigational compound or device within the prior 12 weeks of screening or signing
             the informed consent and does not agree to refrain from participating in any other
             study while participating in this study.

         18. Patient has undergone surgery within the prior 12 weeks or has major surgery planned
             during the study.

         19. Patient is on or is likely to require treatment with equal to/ more than 14
             consecutive days or repeated courses of pharmacologic doses of corticosteroids.

             Note: Inhaled, nasal, and topical corticosteroids are permitted.

         20. Patient has a clinically significant laboratory or ECG abnormality which, in the
             opinion of the investigator, exposes the patient to risk by enrolling in the study.

         21. History of drug abuse or alcohol abuse. History of recreational or illicit drugs used.
             Alcohol abuse includes heavy alcohol intake as defined by more than 2 drinks per day
             or more than 14 drinks per week, or binge drinking.

         22. Patient has a clinically significant haematological disorder (e.g., aplastic anaemia,
             myeloproliferative or myelodysplastic syndromes, thrombocytopenia, thalassaemia or
             thalassaemia trait).

         23. Blood donation 3 months prior to the start of the study and during the whole study
             period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juliana CN CHAN, FRCP, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese University of Hong Kong</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Medicine &amp; Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2011</study_first_submitted>
  <study_first_submitted_qc>January 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2011</study_first_posted>
  <last_update_submitted>August 21, 2015</last_update_submitted>
  <last_update_submitted_qc>August 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Juliana Chan</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>type 2 diabetes mellitus</keyword>
  <keyword>JUBILEE Study</keyword>
  <keyword>Janumet</keyword>
  <keyword>Lantus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Gliclazide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

